FBLG insider transaction filings
FibroBiologics, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-23. Screen FBLG transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Cilento Richard C. Jr. — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Niklas Victoria Ninon Olivia — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Link Matthew — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Hoffman Robert E. — Director | Grant/award (A): 30,803 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Khoja Hamid — Chief Scientific Officer | Grant/award (A): 61,607 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | GARCIA RUBEN A — General Counsel | Grant/award (A): 61,607 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | O'HEERON PETE — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 92,410 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Davis Jason — Chief Financial Officer | Grant/award (A): 61,607 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Khoja Hamid — Chief Scientific Officer | Purchase (P): 30,000 @ $0.38 | EDGAR |
| 2026-03-04 | 4 | O'HEERON PETE — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 17,428 @ $0.35 · Purchase (P): 18,200 @ $0.41 · Purchase (P): 15,872 @ $0.38 | EDGAR |
| 2026-03-03 | 4 | Davis Jason — Chief Financial Officer | Purchase (P): 70,000 @ $0.41 | EDGAR |
| 2026-03-02 | 4 | GARCIA RUBEN A — General Counsel | Purchase (P): 40,000 @ $0.33 | EDGAR |
| 2025-12-12 | 4 | GARCIA RUBEN A — General Counsel | Purchase (P): 140,000 @ $0.34 | EDGAR |
| 2025-06-12 | 4 | Niklas Victoria Ninon Olivia — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Cilento Richard C. Jr. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Coen Stacy Ann — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Link Matthew — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Hoffman Robert E. — Director | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Davis Jason — Chief Financial Officer | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Khoja Hamid — Chief Scientific Officer | Purchase (P): 20,000 @ $0.84 | EDGAR |
| 2025-03-28 | 4 | GARCIA RUBEN A — General Counsel | Grant/award (A): 189,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Khoja Hamid — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 189,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | O'HEERON PETE — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 453,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — FibroBiologics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-24 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FBLG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →